Mardi Dier
CIK: 0001574591
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (37 total)
- Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct80 shares at avg. $436.69$35K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct40 shares at avg. $437.65$18K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct646 shares at avg. $431.94$279K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct40 shares at avg. $425.08$17K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct420 shares at avg. $426.86$179K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct80 shares at avg. $427.85$34K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct160 shares at avg. $429.00$69K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct40 shares at avg. $429.58$17K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct120 shares at avg. $430.90$52K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct116 shares at avg. $432.56$50K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct160 shares at avg. $434.20$69K - Mar 6, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct80 shares at avg. $435.31$35K - Mar 4, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Award(A)Direct5.2K shares- - Mar 2, 2026MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $427.21$505K - Jan 2, 2026ORIC
Oric Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
40K shares- - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct80 shares at avg. $596.18$48K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct320 shares at avg. $570.39$183K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Exercise(M)Direct4.2K shares at avg. $251.63$1.1M - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct410 shares at avg. $571.99$235K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct354 shares at avg. $573.02$203K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct717 shares at avg. $574.00$412K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct120 shares at avg. $574.95$69K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct240 shares at avg. $576.15$138K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct320 shares at avg. $577.81$185K - Dec 2, 2025MDGL
MADRIGAL PHARMACEUTICALS, INC.
Sale(S)Direct258 shares at avg. $578.83$149K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 6, 2026 |  MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 80 | $436.69 | $34,935 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 40 | $437.65 | $17,506 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 646 | $431.94 | $279,033 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 40 | $425.08 | $17,003 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 420 | $426.86 | $179,283 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 80 | $427.85 | $34,228 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 160 | $429.00 | $68,639 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 40 | $429.58 | $17,183 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 120 | $430.90 | $51,708 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 116 | $432.56 | $50,176 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 160 | $434.20 | $69,472 | Direct |
| Mar 6, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 80 | $435.31 | $34,825 | Direct |
| Mar 4, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Award(A) | 5,215 | - | $0 | Direct |
| Mar 2, 2026 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 1,183 | $427.21 | $505,389 | Direct |
| Jan 2, 2026 |  ORIC Oric Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 40,000 | - | - | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 80 | $596.18 | $47,695 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 320 | $570.39 | $182,524 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Exercise(M) | 4,173 | $251.63 | $1,050,052 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 410 | $571.99 | $234,516 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 354 | $573.02 | $202,847 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 717 | $574.00 | $411,559 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 120 | $574.95 | $68,994 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 240 | $576.15 | $138,276 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 320 | $577.81 | $184,901 | Direct |
| Dec 2, 2025 | MDGL MADRIGAL PHARMACEUTICALS, INC. | Sale(S) | 258 | $578.83 | $149,338 | Direct |
1-25 of 37 transactions
About Dier Mardi
Dier Mardi (SEC CIK 0001574591) files insider reports with the SEC as EVP and CFO of MADRIGAL PHARMACEUTICALS, INC. (MDGL), Director of Oric Pharmaceuticals, Inc. (ORIC) and Director of Prelude Therapeutics Inc (PRLD).
Signal8 holds 9 ownership filings by Dier Mardi, all Form 4s, filed between Jan 6, 2025 and Mar 6, 2026. Those filings report 37 transactions, from Jan 2, 2025 to Mar 6, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Dier Mardi's filings is in WEST CONSHOHOCKEN, PA.
Recent filings by Dier Mardi
- Mar 6, 2026: Open-market sales of MDGL shares (12 lines, Form 4, code S).
- Mar 4, 2026: Grant or award of MDGL shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of MDGL shares (Form 4, code S).
- Jan 2, 2026: Grant or award of ORIC derivative securities (Form 4, code A).
- Dec 2, 2025: Open-market sales of MDGL shares (2 lines, Form 4, code S).
Other insiders filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Sibold William John, President and CEO
- Kelley Shannon T, General Counsel
- REED JOHN C, Director
- Taub Rebecca, Director
- Levy Richard S, Director
- FOUSE JACQUALYN A, Director